Literature DB >> 12646614

The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs.

Derry C Roopenian1, Gregory J Christianson, Thomas J Sproule, Aaron C Brown, Shreeram Akilesh, Nadja Jung, Stefka Petkova, Lia Avanessian, Eun Young Choi, Daniel J Shaffer, Peter A Eden, Clark L Anderson.   

Abstract

Abs of the IgG isotype are efficiently transported from mother to neonate and have an extended serum t(1/2) compared with Abs of other isotypes. Circumstantial evidence suggests that the MHC class I-related protein, the neonatal FcR (FcRn), is the FcR responsible for both in vivo functions. To understand the phenotypes imposed by FcRn, we produced and analyzed mice with a defective FcRn gene. The results provide direct evidence that perinatal IgG transport and protection of IgG from catabolism are mediated by FcRn, and that the latter function is key to IgG homeostasis, essential for generating a potent IgG response to foreign Ags, and the basis of enhanced efficacy of Fc-IgG-based therapeutics. FcRn is therefore a promising therapeutic target for enhancing protective humoral immunity, treating autoimmune disease, and improving drug efficacy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12646614     DOI: 10.4049/jimmunol.170.7.3528

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  183 in total

1.  Oligoclonal antibody targeting ghrelin increases energy expenditure and reduces food intake in fasted mice.

Authors:  Joseph S Zakhari; Eric P Zorrilla; Bin Zhou; Alexander V Mayorov; Kim D Janda
Journal:  Mol Pharm       Date:  2011-12-23       Impact factor: 4.939

Review 2.  Regulation of immune responses by CD1d-restricted natural killer T cells.

Authors:  Luc Van Kaer
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

Review 3.  Recent advances using FcRn overexpression in transgenic animals to overcome impediments of standard antibody technologies to improve the generation of specific antibodies.

Authors:  Imre Kacskovics; Judit Cervenak; Anna Erdei; Richard A Goldsby; John E Butler
Journal:  MAbs       Date:  2011-09-01       Impact factor: 5.857

4.  Monoclonal antibodies directed against human FcRn and their applications.

Authors:  Gregory J Christianson; Victor Z Sun; Shreeram Akilesh; Emanuele Pesavento; Gabriele Proetzel; Derry C Roopenian
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

5.  MHC class I family proteins retard systemic lupus erythematosus autoimmunity and B cell lymphomagenesis.

Authors:  Caroline G McPhee; Thomas J Sproule; Dong-Mi Shin; Jason A Bubier; William H Schott; Martin P Steinbuck; Lia Avenesyan; Herbert C Morse; Derry C Roopenian
Journal:  J Immunol       Date:  2011-09-30       Impact factor: 5.422

6.  X-ray crystal structures of monomeric and dimeric peptide inhibitors in complex with the human neonatal Fc receptor, FcRn.

Authors:  Adam R Mezo; Vandana Sridhar; John Badger; Paul Sakorafas; Vicki Nienaber
Journal:  J Biol Chem       Date:  2010-06-30       Impact factor: 5.157

7.  Transepithelial transport of Fc-targeted nanoparticles by the neonatal fc receptor for oral delivery.

Authors:  Eric M Pridgen; Frank Alexis; Timothy T Kuo; Etgar Levy-Nissenbaum; Rohit Karnik; Richard S Blumberg; Robert Langer; Omid C Farokhzad
Journal:  Sci Transl Med       Date:  2013-11-27       Impact factor: 17.956

8.  FcRn in the yolk sac endoderm of mouse is required for IgG transport to fetus.

Authors:  Jonghan Kim; Sudhasri Mohanty; Latha P Ganesan; Keding Hua; David Jarjoura; William L Hayton; John M Robinson; Clark L Anderson
Journal:  J Immunol       Date:  2009-03-01       Impact factor: 5.422

Review 9.  Fc receptors and their role in immune regulation and autoimmunity.

Authors:  Toshiyuki Takai
Journal:  J Clin Immunol       Date:  2005-01       Impact factor: 8.317

10.  Improved tumor imaging and therapy via i.v. IgG-mediated time-sequential modulation of neonatal Fc receptor.

Authors:  Jaspreet Singh Jaggi; Jorge A Carrasquillo; Surya V Seshan; Pat Zanzonico; Erik Henke; Andrew Nagel; Jazmin Schwartz; Brad Beattie; Barry J Kappel; Debjit Chattopadhyay; Jing Xiao; George Sgouros; Steven M Larson; David A Scheinberg
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.